Notably, we observed differences in RUNX3 isoform usage; the longer isoform, p46, may act as a tumor suppressor in BOS [75, 76] while a shorter RUNX3 isoform predominates in AML. This evidence concerns the gene RUNX3 and Buschke-Ollendorff syndrome.